CLOPIDOGREL (CYP2C19 GENOTYPING)

CYP2C19 genotyping is a genetic test that evaluates specific inherited variations in the CYP2C19 gene to determine how an individual might metabolize or respond to certain medications, notably clopidogrel, which is an antiplatelet medication commonly used to prevent heart attacks and strokes in individuals with heart disease. The CYP2C19 enzyme, encoded by the CYP2C19 gene, plays a significant role in the activation of clopidogrel. Variations in the CYP2C19 gene can influence the enzyme’s activity, affecting how well clopidogrel is activated and consequently, how effective it is in preventing blood clots.